The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
about
A Review of the Toxicologic Implications of ObesityPharmacokinetics of drugs in cachectic patients: a systematic reviewRole of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Comparison of 3 body size descriptors in critically ill obese children and adolescents: implications for medication dosing.Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.Modeling tuberculosis in nonhuman primates.A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsPharmacokinetics of bisphenol A in humans following a single oral administration.Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis Chemotherapy RegimensThe allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.Interethnic differences in pharmacokinetics of antibacterials.Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers.Fixed Dosing of Monoclonal Antibodies in Oncology.Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.Clarification of contraceptive drug pharmacokinetics in obesity.Improving Medication Dosing in the Obese Patient.Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation.Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation.Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass.
P2860
Q28082947-7F8DF83E-4958-4C3D-8E75-CE0DE989E46CQ28535322-B4A6DB0C-8951-4062-844B-BB58CA7855E4Q33418378-E91DCFE6-EEE1-478A-97AA-0A368DAF75C2Q33886796-44A918BD-D79F-4833-A9F4-A55F26704D11Q34057390-6377B174-FCF0-44F5-8659-05C79975EE74Q34065300-7EC90A32-3145-4A92-B90C-CFDA1716CF3AQ34299078-E1D3DD35-4B61-48BF-A76A-24FEAF63D9D9Q34331026-4F834408-CE09-4CB3-A647-C6CFC3B038F0Q34570930-A4FC8010-B818-4243-AAA1-29ACB9E0FC2BQ34930509-9C9F3DA9-3F45-4D1D-9E9A-BF3C4F1B6E36Q35193385-3EB20923-AD46-4355-9C27-462A76125890Q35675920-0BB9C71B-4171-4EAC-A326-2A036F368C59Q35762761-8F6BA144-1638-4E72-BC1D-944C0AA4FA04Q35978007-5A8A4C4D-555C-44BA-B24B-758C78FD6A75Q36247129-FF049CAE-1879-40EC-B973-E39CAFD66B33Q36552289-E846B362-BC75-431F-8F69-8D078DEE55C7Q36558387-EF900E06-35D4-4582-8489-BC1EFE7EDBD8Q36558426-551E407F-501D-41CB-90C4-952624689B37Q36987975-81AFC27F-3AC6-41C9-85CD-88D0EB0AC1B8Q37124117-B9472B9C-9874-45E9-9A17-BE581865D930Q37492046-F24A418D-0BE1-4346-9462-F0D24A21D975Q37695055-6F30237B-D927-42D4-9502-1AB77D0C08D6Q38107101-CF673B11-AF58-426D-A1B9-79A5B0C3ADC7Q38266806-0A4B0EA2-F466-4557-B8C6-F09043B5767FQ38487882-A7E03587-14AA-4F30-877A-BD7847C4E616Q38654371-2A64A82D-5E9E-466D-8A70-93C3264950DFQ38696468-6EEEE876-3899-4AD1-927D-CAA688237F95Q38931118-1AB7CCCD-7C9F-4D2E-BFA4-CE29C205E891Q38932206-E844A51F-9422-477E-BF3C-3E6E637C7C81Q38947388-6B3E1913-DA47-45A4-868B-EAA4240384EAQ38950839-1CF55464-8513-48AC-9692-49CBB7C1EAD0Q39353830-F332341F-A239-4053-91DD-89340EC27608Q40544137-D8AAFD4A-DBD9-4640-83AD-95F647CC64A3Q40708086-A25355A4-E9FD-445E-98CF-32A5FD3BAA00Q41696202-3B2D84B0-D9B6-4334-90B2-0850108E240BQ42324302-BF0998F9-37D1-48CF-8D24-BAD6885A778AQ44455948-26B87370-40FC-4E75-809E-04F0C5FBA170Q44751659-72805A67-C386-4B13-B8B4-D4C9CEFAE330Q45873262-004C1FF3-54A6-44BF-9B1D-64E0AB71B8C4Q47563959-D85CEFDF-1393-4FD8-A5F1-0F24287B9D7A
P2860
The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The relationship between drug ...... e published from 2000 to 2007.
@en
The relationship between drug ...... e published from 2000 to 2007.
@nl
type
label
The relationship between drug ...... e published from 2000 to 2007.
@en
The relationship between drug ...... e published from 2000 to 2007.
@nl
prefLabel
The relationship between drug ...... e published from 2000 to 2007.
@en
The relationship between drug ...... e published from 2000 to 2007.
@nl
P2093
P2860
P1476
The relationship between drug ...... e published from 2000 to 2007.
@en
P2093
Bruce Green
Carl M J Kirkpatrick
Glynn A Morrish
Sarah C McLeay
P2860
P304
P356
10.2165/11598930-000000000-00000
P577
2012-05-01T00:00:00Z
P6179
1022314898